!-- Global site tag (gtag.js) - Google Analytics -->
Select Page
We Add Cisco Systems Back Again, After 20 Years. It's Time

We Add Cisco Systems Back Again, After 20 Years. It's Time

Cisco (CSCO: $50)

Coverage initiated June 1, 2023 at $50 in the Long-Term Growth portfolio

Silicon Valley-based Cisco Systems (CSCO) stands as a shining example of a promising wunderkind that continuously pushes the boundaries of its potential. The four-decades-old company, which was once pegged to be the first trillion-dollar company, still trades below its all-time high of $77 during the dotcom bubble 24 years ago, despite a multifold rise in revenues, profits, and free cash flows during the same period. For years, the company has consistently pioneered groundbreaking new innovations, either via in-house developments, acquisitions, or partnerships, only to lose ground to fresh upstarts in those very segments. A prime example of this is WebEx, its video conferencing solution that was thoroughly outstripped by Zoom, despite having a head start and an established base of enterprise customers.

That being said, however, Cisco is far from the boring tech conglomerate that its valuations currently reflect. While the company is no longer plastered in headlines, or a mainstay in tech conversations as it once was, its products still play a crucial role in the broader ecosystem, particularly in its core networking business. This is precisely what makes the company such a compelling buy, especially at current valuations.

Enviable Product Mix

Cisco makes a broad range of networking and communication equipment that has long been dubbed the ‘backbone of the internet.’ From routers and switches to industrial networking and data center infrastructure, the company is an indisputable giant in this segment, with a market share of over 45% in ethernet switches. Gartner consistently crowns it as the lead in wired and wireless infrastructure.

During its third quarter results two weeks ago, the company posted a robust performance across the board, in the face of headwinds such as inflationary pressures, supply chain issues, unpredictable market dynamics, and economic uncertainties, among other things. We see this as a testament to Cisco’s products and services, which are still the backbone of networking infrastructure across enterprise organizations.

In addition to this, the company is now a sizable player in the hyperscale and AI markets, with its Silicon One Architecture, which is known for its efficient power consumption, which is crucial for hyperscale. Its recent acquisitions of ThousandEyes and AppDynamics have helped further bolster its profile in the observability space, which has since grown to become a vital element of the hybrid work environment. What is hyperscale?  Hyperscale describes a system or technology architecture's ability to scale as demand for resources gets added to it. Examples of hyperscalers are Amazon AWS, Microsoft Azure, Google GCP, Alibaba AliCloud, IBM, and Oracle. As you can see, Cisco is right smack in the middle of this huge growth market.

Recurring Revenue

One reason Cisco has continued to underperform its big-tech rivals is its overreliance on hardware. In general, hardware companies come with a lot of baggage and are more prone to macro headwinds such as the present supply-chain constraints and inflationary pressures. Excepting Apple, hardware is a tough spot to be in this day and age.

Over a decade ago, Cisco recognized the importance of this and has since consistently strived for and witnessed a transition towards services and recurring revenues throughout its product range. While hardware still remains at the core of its offerings, starting in 2012, the company has quietly transitioned into a machine for services and recurring subscriptions, and this is precisely what our investment thesis is currently based on.

This was the logical next step for the company in order to build steady revenues. After all, even at large enterprises, it is rather rare to upgrade switches, access points, and firewalls on a regular basis. This transition has since paid off handsomely, with Cisco reporting monumental growth in subscription revenues, and in increasing remaining performance obligations, at $6 billion and $17 billion, respectively.

This shift has fundamentally altered the outlook of this stock, from being a low-margin peddler of utilities to a scalable, predictable, and largely low-overhead operating model. This shift further makes the company more resilient in challenging times, making it less prone to macro shocks, as no matter how dire the situation gets, large enterprises are unlikely to scale back on their wireless infrastructure.

Risk Factors

While this decade-long transformation has been off to a great start, it is not without its risks, or at least certain presumed risks. In recent months, investors have grown increasingly concerned about the company losing market share in its core networking business. Its well-known customers have been leaving in droves in favor of competitors such as Juniper Networks and Arista Networks.

This, however, is largely overblown in our opinion, as the company, being the dominant player in the market, is more prone to macro shocks, and will further bear the brunt of most competitive pressures as opposed to players with a smaller share of the pie. As a result, the stock has remained under pressure over the past few months, but things will subside as better sense starts to prevail.

Financial Analysis

The last four years of revenues have been solid, but flat. The company hit $52 billion in 2019 and then was hurt by the pandemic in 2020 and 2021 reporting $49 billion and $50 billion respectively. Fiscal 2022 ending in July last year saw $51.5 billion, and the company did $14.7 billion in the quarter ending April 30th, 2023, giving it a run-rate of $59 billion. The company is quite profitable, producing $4.1 billion in profits last quarter, a profitability rate of a huge 28% after tax. Very strong. Guidance: The company has predicted future growth rates of revenues at 15%, earnings per share of $1.05 for the quarter, and $3.80 cents for the full year ending July 31, 2023.

From the company in its recent quarterly report: Capital Allocation -- In the third quarter of fiscal 2023, we returned $2.9 billion to stockholders through share buybacks and dividends. We declared and paid a cash dividend of $0.39 per common share, or $1.6 billion, and repurchased approximately 25 million shares of common stock under our stock repurchase program at an average price of $49.45 per share for an aggregate purchase price of $1.3 billion. The remaining authorized amount for stock repurchases under the program is $12.2 billion with no termination date.

Icing On The Cake

Cisco’s core business, products, and fundamentals are beyond reproach, and now comes the icing on the cake, which is the company’s generous capital returns program. Since instituting its dividend program in 2011, it has been increased consecutively for 11 years, marking a 550% increase as of today. This represents an annualized yield of 3.1%, with a payout ratio of 43%, the best among the tech giants.

In addition to this, the company is all the more generous when it comes to its stock buybacks, having repurchased nearly 25% of its total shares outstanding since the end of 2013. During its recent third quarter results, the company similarly announced $1.6 billion in dividends and $1.3 billion in buybacks, with a further $12.2 billion in repurchase authorizations pending, with no expiration date mentioned.

All of this shows management’s confidence in the company’s steady cash flows, especially as it transitions to the subscription-based model. On top of this, the company has made remarkable strides when it comes to profit margins and free cash flow yields, in the face of substantial macro headwinds, ranging from inflation, supply issues, and waning demand.

BMR Take

Cisco is an outlier among the big-tech giants, trading at under 4 times sales, and a mere 12 times its free cash flow.  During its third quarter results two weeks ago, the company posted a handy beat on estimates, with $14.6 billion in revenues, up 14% YoY, and a profit of $4.1 billion, or $1.00 per share. This was in addition to the boost in guidance figures, and yet the stock received a somber reception when the markets opened the following day. The company has $23 billion in cash, up from $19 billion last year, and less than $10 billion in debt. Cash Flow from Operating Activities -- $5.2 billion for the third quarter of fiscal 2023, an increase of 43% compared with $3.7 billion for the third quarter of fiscal 2022.

All of this points towards substantial coiled potential that is just waiting to be released, apart from the robust technical factors, with the RSI already above 75 and continuing to gain strength week after week, following the results. The old is forever new again. We believe we have found a diamond in the rough and we will be rewarded in the company years with the continued growth of big tech, electronics, wireless, computing power, networking, mobile and the like. Or, we could have just said we believe in Moore’s Law. Long live Gordon Moore’s legacy.

Added to our Long Term Growth Portfolio today, our initial Target is $60 with a Sell Price of $41. But we can see the day when Cisco hits triple digits.

 

Big Healthcare Prospects, Big Backing: Agilent

Big Healthcare Prospects, Big Backing: Agilent

Agilent (A: $84)


 

Coverage initiated December 16, 2019 at $84 in the HEALTHCARE portfolio.
NOTE: To view current Target & Sell Prices press the back arrow and click on the plus sign (+) next to the name of the stock.

 

Company Overview. Agilent is a Healthcare company that was spun out of Hewlett-Packard in 1999. At the time, it was the largest IPO in Silicon Valley history. The company improves the laboratory workflow by providing analytical instruments, software, and various other services that enhance quality and efficiency. The company also provides lab management services, including asset management, equipment management, laboratory business intelligence, software maintenance, and genomics and cloning.

 

Business Model. Management divested the company of several underperforming business lines during the early 2000s, when economic uncertainty reduced demand for Healthcare products. The company subsequently sold its semiconductor business to private equity companies for nearly $3 billion. The company also sold off its Healthcare and medical products divisions to Phillips Medical Systems for $11 billion. The dual-sales effort was part of a strategic decision to concentrate more fully on the laboratory test/measurement business.

 

Since 2010, the company has grown its core business line through both innovative product offerings and strategic M&A activity. Luxcel Biosciences, Lasergen, ProZyme, Genohm and Advanced Analytical Technologies are just some of the acquisitions the company has made in 2018 alone. Clearly, management has a growth strategy predicated on purchasing strong, nascent companies that enhance the product line and help attract and retain customers.

 

Competitive Analysis. Healthcare is a vast sector, with many large subsectors full of competing organizations. As a laboratory workflow manufacturer, Agilent occupies one of the more niche areas of Healthcare. Prominent and publicly-traded competitors include Thermo Fisher Scientific, Abbott Labs, Bruker Corporation, Shimadzu, ULVAC Technologies and Bio-Rad. Thermo Fisher and Abbott are by far the largest players in the space, with 70,000 and 100,000 employees, respectively. Thermo Fisher has a $130 billion valuation, and Abbott has a $150 billion valuation. By comparison, Agilent has about 16,000 employees and is valued at $26 billion.

 

That said, Agilent is the third-largest player in the space. It’s worth noting that both Abbott’s and Thermo Fisher’s revenue and net income have been soaring over the past couple of years. Abbott’s revenue rose 50% from 2017-2019, to $31 billion, and net income rose from $480 million at the start of 2018 to $2.4 billion at the beginning of 2019. Thermo Fisher’s revenue grew 30% in the two years from 2017-2019, and its net income rose 50% during that same time, to $3 billion.

 

The revenue and net income growth of the two major players in the space is a strong sign for the broader laboratory workflow sector, as it implies a robust demand for the products and services that the sector provides. Also, a rising tide lifts all boats, and as the third-largest ship in this ocean, Agilent is poised to benefit from both Abbott’s and Thermo Fisher’s rapid growth.

 

Financial Analysis. Agilent has strong financials. 3Q19 (which was the company’s fourth quarter) came in robust, with revenue of $1.3 billion up 6% YoY. Earnings were almost $200 million. Fiscal year revenue of $5.2 billion grew 5% YoY, and EPS of $3.37 was up a whopping 250% YoY. The company is guiding next year’s fiscal year revenue at 4-5% growth once again, and earnings guidance is expected to tick up slightly, as the company ramps up its M&A and sales and marketing efforts to continue to grow.

 

The company has a market cap of $26 billion, with cash of $1.4 billion and debt of $2.4 billion. That’s not bad for a Healthcare company, which generally assumes high levels of debt. All that cash has come by way of the company growing earnings at an average clip of 17% per year over the last three years. Revenue has been growing at 8% over that same time frame, and management has done an excellent job of keeping operational costs down.

 

Stock Performance. The stock has performed in-line with the broader market this year, up 27% YTD. The 1% annual yield puts it right on the S&P’s YTD return. The stock is currently at its all-time high. Yet this is clearly the brightest point in the company’s history, as Agilent spent a good chunk of years disposing of underperforming business lines and ramping its core laboratory workflow business. The company is in terrific shape today, and its spate of mergers and acquisitions illustrate the strong financial and fundamental position of the company. Management is dead-set on growth, and has the cash on hand to continue to fulfill its M&A strategy. The stock has reflected the excellent forward-looking prospects for this company.

 

Agilent is mainly held by institutional investors like T. Rowe Price, BlackRock, Fidelity and Vanguard. That’s a good sign, as heavy hitters in the Financial Analysis space are on board with the stock. The stock even got a boost recently when Bill Ackman’s Pershing Square announced a purchase of nearly 3 million shares, with the distinct possibility of future buy-ins. Ackman is a legendary hedge fund manager, so his investment into Agilent really means something.

 

BMR TAKE: Agilent is a growing company in a growing sector. The financials are strong, with solid revenue and earnings growth year-over-year. On top of that, management’s M&A strategy is accretive, and shows that the company is willing to improve its products and services by purchasing rising stars in the sector and absorbing them and synergizing the costs. The growth of both Abbott Labs and Thermo Fisher shows how popular the sector is, and what high demand exists for laboratory workflow companies – and that spells great news for the third-largest player in the space, that continues to make proactive strategic growth decisions.

 

What’s more, the recent investment by Bill Ackman, which only adds to the laundry list of institutional brand names aboard this stock, signals confidence by some of Wall Street’s best investment professionals. While not a reason to invest in a stock alone, it’s good to know that major hedge funds and investment firms are participating in the Agilent growth story.

 

Management has steered this company through some tough times, disposing of key business lines, reducing staff, and guiding the company through the pressure of a low-demand climate. Demand for laboratory services is growing, and management is intent on growing the company to take advantage of the boom times. We’re expecting big things from this stock next year as a result.

 

 

Apple

Apple

Is Apple a growth stock or a value stock? Let’s take a look at the values. Cash and Investments equal about $40 per share, about 44% of the current market value of the company. Take out that cash and it leaves a value of only 6 times earnings...

This content is for our beloved subscribers and anything you see on this page is just an excerpt!

Please note BullMarket.com access is available to paid subscribers only. Our Members Areas include archives of past Newsletters, News Flashes, our eight portfolios including STOCKS FOR SUCCESS, Healthcare, High Yield, High Technology, Aggressive, Real Estate Investment Trusts, Long Term Growth, and Special Opportunities. Also, all of our in-depth research is available, and more.

Already a subscriber?

Ready to join?
Subscribe Now!

Welltower Research Report (WELL)

With over 1400 properties, Welltower is the biggest healthcare dedicated REIT in this large, growing and highly fragmented field.

This content is for our beloved subscribers and anything you see on this page is just an excerpt!

Please note BullMarket.com access is available to paid subscribers only. Our Members Areas include archives of past Newsletters, News Flashes, our eight portfolios including STOCKS FOR SUCCESS, Healthcare, High Yield, High Technology, Aggressive, Real Estate Investment Trusts, Long Term Growth, and Special Opportunities. Also, all of our in-depth research is available, and more.

Already a subscriber?

Ready to join?
Subscribe Now!

Visa

Visa

Visa is not a bank, although to many credit card holders, it may feel like one. In reality Visa doesn’t take deposits or lend money. It has no branches or ATM machines. It assumes no credit risk. It never even touches the billions of plastic cards that bare its name and familiar logo...

This content is for our beloved subscribers and anything you see on this page is just an excerpt!

Please note BullMarket.com access is available to paid subscribers only. Our Members Areas include archives of past Newsletters, News Flashes, our eight portfolios including STOCKS FOR SUCCESS, Healthcare, High Yield, High Technology, Aggressive, Real Estate Investment Trusts, Long Term Growth, and Special Opportunities. Also, all of our in-depth research is available, and more.

Already a subscriber?

Ready to join?
Subscribe Now!

Blackstone

Blackstone

Investors looking to participate broadly in the global financial markets need look no further than The Blackstone Group L.P. They are a highly respected global alternative asset manager, the largest in the world. Unlike Morgan Stanley or Merrill Lynch who specialize in publically traded stocks and bonds for institutions and individuals, Blackstone is different...

This content is for our beloved subscribers and anything you see on this page is just an excerpt!

Please note BullMarket.com access is available to paid subscribers only. Our Members Areas include archives of past Newsletters, News Flashes, our eight portfolios including STOCKS FOR SUCCESS, Healthcare, High Yield, High Technology, Aggressive, Real Estate Investment Trusts, Long Term Growth, and Special Opportunities. Also, all of our in-depth research is available, and more.

Already a subscriber?

Ready to join?
Subscribe Now!